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We aimed to evaluate 10 biomarkers related to inflammation and the kynurenine pathway, including neopterin,
kynurenine:tryptophan ratio, C-reactive protein, tryptophan, and 6 kynurenines, as potential predictors of all-cause
and cause-specific mortality in a general population sample. The study cohort was participants involved in a
community-based Norwegian study, the Hordaland Health Study (HUSK). We used Cox proportional hazards mod-
els to assess associations of the biomarkers with all-cause mortality and competing-risk models for cause-specific
mortality. Of the 7,015 participants, 1,496 deaths were recorded after a median follow-up time of 14 years (1998–
2012). Plasma levels of inflammatory markers (neopterin, kynurenine:tryptophan ratio, and C-reactive protein),
anthranilic acid, and 3-hydroxykynurenine were positively associated with all-cause mortality, and tryptophan
and xanthurenic acid were inversely associated. Multivariate-adjusted hazard ratios for the highest (versus lowest)
quartiles of the biomarkers were 1.19–1.60 for positive associations and 0.73–0.87 for negative associations. All of
the inflammatory markers and most kynurenines, except kynurenic acid and 3-hydroxyanthranilic acid, were asso-
ciated with cardiovascular disease (CVD) mortality. In this general population, plasma biomarkers of inflammation
and kynurenines were associated with risk of all-cause, cancer, and CVD mortality. Associations were stronger for
CVD mortality than for mortality due to cancer or other causes.
cancer; cardiovascular disease; inflammation; mortality; tryptophan
Abbreviations: AA, anthranilic acid; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration
rate; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; ICD-10, International Classification of Diseases, Tenth Revision;
KA, kynurenic acid; KTR, kynurenine:tryptophan ratio; XA, xanthurenic acid.
Persistent systemic inﬂammation predisposes people to
chronic disease and death (1). The proinﬂammatory cyto-
kine interferon-γ induces the production of neopterin, a
macrophage-derived metabolite. It also activates indoleamine
2,3-dioxygenase, which catalyzes the ﬁrst and rate-limiting
step in the kynurenine pathway of tryptophan catabolism,
where tryptophan is converted to a variety of immunomo-
dulating and neuroactive compounds, collectively termed
kynurenines (2, 3).
The kynurenine pathway ultimately results in the biosyn-
thesis of nicotinamide adenine dinucleotide. The pathway
involves vitamin B6- or B2-dependent enzymes catalyzing
the formation of kynurenines, including anthranilic acid
(AA), kynurenic acid (KA), 3-hydroxykynurenine (HK), 3-
hydroxyanthranilic acid (HAA), and xanthurenic acid (XA)
(4, 5) (Figure 1). The kynurenine pathway is well balanced
under physiological conditions but up-regulated as part of
the activated immune response (5), and it has been linked
to several diseases, including neurodegenerative disorders,
depression, and cancer (5).
Plasma neopterin level and kynurenine:tryptophan ratio
(KTR) are correlated and are often considered systemic
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inﬂammatory markers reﬂecting interferon-γ activity (5, 6).
Plasma neopterin has been found to predict all-cause mortal-
ity in patients with stable angina pectoris (6) and in renal
transplant recipients (7). KTR in plasma or urine predicts all-
cause and cardiovascular disease (CVD) mortality in patients
with stable angina pectoris (6, 8) and mortality in human im-
munodeﬁciency virus–infected adults (9). Elevated neopterin
level and KTR have been associated with increased risk of
future coronary events (10) and cancer (11) and with more
advanced stages of cancer (12).
C-reactive protein (CRP) reﬂects the activity of interleukin-
6, a mediator of inﬂammatory cascades (13). It is a nonspeciﬁc
systemic marker of inﬂammation. Elevated CRP level is a
well-documented risk factor for CVD outcomes (14) and is
a possible risk factor for cancer (11, 15), diabetes (16, 17),
and fractures (18, 19), conditions that contribute to increased
morbidity and mortality. Previous studies have demonstrated
associations of CRP with all-cause mortality (14, 20) and
death from vascular and nonvascular diseases, including can-
cer and respiratory diseases (13, 21, 22).
To date, there have been no published studies on pro-
spective associations of biomarkers related to interferon-γ-
mediated inﬂammation and the kynurenine pathway with
mortality risk in the general population. Our aim in this study
was to evaluate levels of interferon-γ-mediated inﬂammatory
markers (neopterin and KTR), tryptophan, and 6 kynure-
nines, in addition to CRP, as potential predictors of all-cause
and cause-speciﬁc mortality in a large community-based
cohort.
METHODS
Study population
Datawere drawn from theHordalandHealth Study (HUSK)
(23), in which baseline examinations were conducted in
Hordaland County, western Norway, in 1998–1999 (http://
husk.b.uib.no). The study population consisted of 7,051
men andwomen born during 1925–1927 and 1950–1951who
had previously (1992–1993) participated in the Hordaland
Homocysteine Study (24). We excluded participants with
missing blood measurements at baseline (n = 35) and with
missing information on vital status (n = 1). The cohort for all-
cause mortality comprised 7,015 participants (3,117 men and
3,898 women). For the analysis of cause-speciﬁc mortality,
we further excluded participants who died during the follow-
up period but had no information on cause of death (n = 5);
this yielded 7,010 participants. The Regional Committee for
Medical and Health Research Ethics in Western Norway
approved the study protocol, and all participants gave signed
informed consent at baseline.
Laboratory measurements
Nonfasting blood samples were collected at baseline. Ali-
quots of ethylenediaminetetraacetic acid plasma were frozen at
−80°C until analyses. Plasma levels of neopterin, tryptophan,
and 6 kynurenines (kynurenine, AA, KA, HK, HAA, and
XA) were measured by means of liquid chromatography–
tandem mass spectrometry (25). KTR was calculated as the
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Figure 1. The kynurenine pathway of tryptophan catabolism and markers of interferon-γ-mediated immune activation. 3HAO, 3-
hydroxyanthranilate dioxygenase; IDO, indoleamine 2,3-dioxygenase; IFN-γ, interferon-γ; KAT, kynurenine transaminase; KFO, kynurenine formy-
lase; KMO, kynurenine monooxygenase; KTR, kynurenine:tryptophan ratio; KYNU, kynureninase; NAD+, nicotinamide adenine dinucleotide;
QPRT, quinolinate phosphoribosyl transferase; TDO, tryptophan 2,3-dioxygenase.
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ratio of the concentrations of kynurenine (in nmol) to the con-
centrations of tryptophan (in µmol). Plasma high-sensitivity
CRP level was determined using an immuno-MALDI [matrix-
assisted laser desorption/ionization] mass spectrometry method
(26). For neopterin and the 6 kynurenines, limits of detection
ranged from 0.5 nmol/L to 7 nmol/L, while the limit was 0.4
µmol/L for tryptophan.Within-dayandbetween-day coefﬁcients
ofvariationwere3.0%–9.5%and5.7%–16.9%, respectively.For
CRP, the limit of detection was 0.1 mg/L, and within-day and
between-day coefﬁcients of variation were 3.3%–5.5% and
2.4%–7.0%, respectively. Serum creatininewasmeasured color-
imetrically using the alkaline picrate method with reagents from
Roche (Basel, Switzerland) (23). All biochemical analyses were
performedatBevitalA/S(Bergen,Norway;www.bevital.no),ex-
cept for serum creatinine, which was analyzed at Ullevål
University Hospital (Oslo, Norway).
Follow-up and ascertainment of deaths
Follow-up began at baseline and ended at the date of death,
emigration, or the end of follow-up period,whichever cameﬁrst.
Deaths were included in the analysis if they occurred between
baseline and the end of the follow-up period. Information on all-
cause mortality was collected by linkage with Statistics Norway
(through the year 2012) and information on cause-speciﬁc
mortality by linkage with the Cause of Death Registry (through
the year 2011). Primary cause of death was coded according to
the 2010 version of the International Classiﬁcation of Diseases,
Tenth Revision (ICD-10). Deaths due to cancer (ICD-10 codes
C00–C97), CVD (ICD-10 codes I00–I99), all other diseases,
and external causes (ICD-10 codes V01–Y98) were combined.
Other baseline variables
Sociodemographic covariates includedsexandage.Dataon
lifestyle measures, including smoking (never, former, or cur-
rent smoker) and physical activity (none/light or moderate/
vigorous),were collected byself-administered questionnaires.
Body mass index was calculated as weight in kilograms di-
vided by height in meters squared and was used as a contin-
uous covariate. Calculation of estimated glomerular ﬁltration
rate (eGFR), which reﬂects renal function, was based on
serum creatinine levels using the Chronic Kidney Disease
Epidemiology Collaboration equation (27).
Information on history of cancer (diagnosed with cancer be-
fore baseline, other than nonmelanoma skin cancer) was ob-
tained through linkage with the Cancer Registry of Norway.
InformationonCVD(myocardial infarction,angina,andstroke)
at baseline was self-reported. Participants were considered to
have diabetes at baseline if they reported use of hypoglycemic
medication or had a blood glucose level ≥126 mg/dL (time
since last meal≥8 hours) or ≥200 mg/dL (time since last meal
<8 hours) (28). The numbers of participants with histories of
cancer, CVD, and diabetes at baseline were 422, 719, and 192,
respectively. A total of 1,189 participants had a history of mor-
bidity, including cancer, CVD, or diabetes.
Statistical analysis
Analyses were performed using SAS 9.2 (SAS Institute,
Inc., Cary, North Carolina) and R, version 3.0.3 for Windows
(cmprsk and survival package; R Foundation for Statistical
Computing,Vienna, Austria (www.r-project.org)). Log trans-
formation was applied to all plasma biomarkers to normalize
their distributions. Summary statistics for continuous vari-
ables are reported asmedian values (with interquartile ranges)
and categorical variables as percentages. Differences between
decedents and those remaining alive during follow-up were
compared using χ2 tests for categorical variables andWilcoxon-
Mann-Whitney tests for continuous variables. Pearson correla-
tion coefﬁcients were calculated to examine the relationships of
plasma CRP with tryptophan and kynurenines. Other rela-
tionships between the biomarkers have been previously re-
ported (11, 29).
For the analysis of all-cause mortality, we used Cox pro-
portional hazards models to calculate hazard ratios and
95% conﬁdence intervals. The models were tested and plot-
ted based on scaled Schoenfeld residuals (30) to ensure that
assumptions of proportional hazards were not violated.
Plasma measures were analyzed both as sex-speciﬁc quartiles
and on continuous scales (per standard-deviation increment
after log transformation). Associations between exposures
and risk of all-cause mortality were visualized using general-
ized additive model regression plots. For the analysis of
cause-speciﬁc mortality, we used competing-risk models to
account for competing events (31, 32). Multivariate models
included adjustment for sex, age group (46–49 years vs.
70–74 years), bodymass index (continuous), smoking (never,
former, or current smoker), and eGFR (continuous). Addition
of interaction terms for interaction between sex and all expo-
sures in models of mortality risk suggested no differences in
predictor-outcome associations between the sexes (P for
interaction > 0.05). Therefore, we combined men and women
in the analyses.
Sensitivity analyses were conducted to assess the robustness
of our results. We restricted the analyses to those participants
who had no history of cancer, CVD, or diabetes at baseline.
Moreover, we replicated the analyses by excluding the ﬁrst 5
years of follow-up to eliminate the possible contribution of pa-
tients with preexisting disease that was fatal within the ﬁrst 5
years of follow-up. All tests were 2-sided, and a P value less
than 0.05 was considered statistically signiﬁcant.
RESULTS
Population characteristics at baseline
Among the 7,015 participants, 1,496 deaths (817 men and
679 women) were recorded after a median follow-up time of
13.9 years (range, 0.1–14.7 years). Baseline characteristics of
participants by vital status are shown in Table 1. A higher
proportion of those who died during follow-up were male,
and they were older at baseline (P < 0.001). In addition, de-
cedents had a higher baseline body mass index and decreased
renal function as estimated by eGFR. A signiﬁcantly higher
percentage of decedents were former smokers and engaged in
less physical activity.Moreover, theyweremore likely to report
a baseline history of cancer, CVD, or diabetes. Decedents had
higher levels of inﬂammatory markers and kynurenines (other
than XA, which was lower) and lower levels of tryptophan at
baseline than their counterparts (P < 0.001).
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Correlations of CRP with other biomarkers
The inﬂammatory markers CRP, KTR, and neopterin
were positively intercorrelated, as reported previously (11).
Plasma CRP was positively correlated with kynurenine (r =
0.17, P < 0.01), HK (r = 0.15, P < 0.01), and HAA (r = 0.11,
P < 0.01) and negatively correlated with XA and tryptophan
(r =−0.04 and P < 0.01 for both catabolites) in age- and sex-
adjusted analyses.
Mortality risk
As shown in Table 2, the 3 inﬂammatory markers (neo-
pterin, KTR, and CRP), kynurenine, AA, and HK were pos-
itively associated with risk of all-cause mortality both in
models adjusted for sex and age only and in fully adjusted
models (with further adjustment for body mass index, smok-
ing, and eGFR). Tryptophan and XA were inversely associ-
ated with mortality risk. There were no linear associations of
Table 1. Baseline Characteristics of Participants After a Median of 14 Years of Follow-up, by Vital Status, Hordaland
Health Study, 1998–2012
Characteristic
Vital Status
P
ValueaOverall (n = 7,015) Alive (n = 5,519) Deceased (n = 1,496)
% Median (IQR) % Median (IQR) % Median (IQR)
Age group, years
46–49 52.8 64.5 9.5 <0.001
70–74 47.2 35.5 90.5
Male sex 44.4 41.7 54.6 <0.001
Duration of follow-up, years 13.9 (13.6, 14.2) 14.1 (13.8, 14.3) 9.3 (5.7, 11.8) <0.001
Body mass indexb 25.4 (23.1, 27.9) 25.3 (23.1, 27.8) 25.7 (23.2, 28.4) 0.004
Smoking status
Never smoker 40.7 42.6 33.4 <0.001
Former smoker 33.7 31.5 41.7
Current smoker 25.6 25.9 24.9
Physical activity level
None/light 43.7 39.2 61.1 <0.001
Moderate/vigorous 56.3 60.8 38.9
eGFR, mL/minute/1.73 m2 79.9 (68.9, 89.7) 82.2 (71.6, 92.0) 70.9 (62.9, 81.0) <0.001
Prevalent disease at baseline
Cancerc 6.0 4.1 13.0 <0.001
Cardiovascular disease 10.3 6.4 24.5 <0.001
Diabetes 2.7 1.4 7.6 <0.001
Inflammatory markers
Neopterin, nmol/L 7.63 (6.37, 9.32) 7.37 (6.21, 8.90) 8.77 (7.26, 11.1) <0.001
Kynurenine:tryptophan ratio,
nmol/µmol
22.6 (18.5, 28.0) 21.6 (18.0, 26.5) 26.6 (21.8, 32.5) <0.001
C-reactive protein, mg/L 1.59 (0.69, 3.62) 1.40 (0.60, 3.24) 2.28 (1.13, 5.27) <0.001
Kynurenine pathway
metabolites
Tryptophan, µmol/L 67.0 (58.3, 76.6) 67.8 (58.9, 77.3) 64.3 (55.8, 74.2) <0.001
Kynurenine, µmol/L 1.52 (1.27, 1.83) 1.48 (1.24, 1.76) 1.72 (1.44, 2.05) <0.001
Anthranilic acid, nmol/L 14.2 (11.4, 18.0) 13.8 (11.1, 17.2) 16.2 (12.7, 20.4) <0.001
Kynurenic acid, nmol/L 45.7 (35.9, 58.5) 44.4 (35.4, 56.3) 50.9 (38.5, 67.6) <0.001
3-Hydroxykynurenine,
nmol/L
32.2 (25.7, 40.3) 31.4 (25.0, 38.7) 36.2 (29.2, 45.7) <0.001
3-Hydroxyanthranilic acid,
nmol/L
33.4 (26.1, 42.8) 33.2 (26.1, 42.3) 34.4 (26.3, 45.0) 0.002
Xanthurenic acid, nmol/L 15.6 (11.3, 21.3) 15.8 (11.5, 21.3) 15.1 (10.5, 21.2) <0.001
Abbreviations: eGFR, estimated glomerular filtration rate; IQR, interquartile range.
a Difference between the alive and deceased groups.
b Weight (kg)/height (m)2.
c Diagnosed cancers other than nonmelanoma skin cancer.
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KA andHAAwith risk of all-cause mortality. Results derived
using quartiles and continuous scales were consistent for all
of the exposures. After additional adjustment for physical ac-
tivity (none/light and moderate/vigorous) or plasma CRP
level, these associations remained essentially unchanged. As-
sociations between kynurenines and all-cause mortality were
attenuated by additional adjustment for neopterin (Appendix
Table1).Therewerenosigniﬁcant interactionswith age for the
majority of these markers, except KTR (P for interaction =
0.05), kynurenine (P for interaction = 0.03), and HAA (P
for interaction = 0.01). Age-stratiﬁed analyses showed that
the risk estimates for the 3 markers were somewhat higher in
the younger age group than in the older one.
Nonlinear associations were explored by means of a general-
ized additive model, which showed positive associations with
mortality in the upper ranges of neopterin, KTR, CRP, kynure-
nine, AA, and HK, inverse associations for tryptophan and in
the lower range of XA, and a U-shaped association for KA
(Figure 2).
In sensitivity analyses, restricting the study population to
5,826 participants with no history of cancer, CVD, or diabe-
tes at baseline gave essentially the same associations as for
Table 2. Hazard Ratios for All-Cause Mortality According to Levels of Inflammatory Markers and Kynurenine Pathway Metabolites (n = 7,015),
Hordaland Health Study, 1998–2012
Biomarker and Model
Quartile of Biomarker Level
P for
Trend
Continuousa
1 2 3 4
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Neopterin, nmol/L
Sex- and age-adjusted 1.00 Referent 1.07 0.88, 1.29 1.14 0.95, 1.37 1.54 1.29, 1.83 <0.001 1.27 1.20, 1.33
Multivariate-adjustedb 1.00 Referent 1.09 0.90, 1.32 1.14 0.95, 1.38 1.55 1.29, 1.86 <0.001 1.28 1.21, 1.36
Kynurenine:tryptophan ratio,
nmol/µmol
Sex- and age-adjusted 1.00 Referent 1.16 0.95, 1.42 1.34 1.11, 1.61 1.60 1.34, 1.92 <0.001 1.22 1.16, 1.29
Multivariate-adjusted 1.00 Referent 1.14 0.93, 1.39 1.34 1.11, 1.63 1.60 1.32, 1.94 <0.001 1.23 1.16, 1.31
C-reactive protein, mg/L
Sex- and age-adjusted 1.00 Referent 1.27 1.05, 1.52 1.30 1.09, 1.56 1.60 1.34, 1.90 <0.001 1.22 1.15, 1.30
Multivariate-adjusted 1.00 Referent 1.25 1.04, 1.50 1.22 1.02, 1.47 1.49 1.24, 1.78 <0.001 1.18 1.11, 1.25
Tryptophan, µmol/L
Sex- and age-adjusted 1.00 Referent 0.90 0.79, 1.03 0.80 0.70, 0.92 0.70 0.60, 0.81 <0.001 0.85 0.81, 0.90
Multivariate-adjusted 1.00 Referent 0.93 0.81, 1.06 0.85 0.74, 0.99 0.73 0.63, 0.85 <0.001 0.87 0.83, 0.92
Kynurenine, µmol/L
Sex- and age-adjusted 1.00 Referent 0.86 0.72, 1.03 0.87 0.73, 1.02 1.10 0.94, 1.29 0.027 1.09 1.03, 1.16
Multivariate-adjusted 1.00 Referent 0.92 0.76, 1.10 0.93 0.78, 1.10 1.18 0.99, 1.41 0.011 1.11 1.04, 1.18
Anthranilic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.90 0.75, 1.07 0.91 0.77, 1.07 1.05 0.90, 1.23 0.180 1.05 1.00, 1.11
Multivariate-adjusted 1.00 Referent 0.95 0.80, 1.14 1.02 0.86, 1.21 1.19 1.01, 1.41 0.006 1.10 1.04, 1.17
Kynurenic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.74 0.63, 0.87 0.72 0.62, 0.84 0.90 0.78, 1.03 0.460 1.00 0.95, 1.05
Multivariate-adjusted 1.00 Referent 0.80 0.68, 0.94 0.76 0.64, 0.89 0.89 0.76, 1.05 0.318 0.99 0.93, 1.06
3-Hydroxykynurenine, nmol/L
Sex- and age-adjusted 1.00 Referent 0.97 0.81, 1.15 0.98 0.83, 1.15 1.28 1.10, 1.49 <0.001 1.18 1.12, 1.24
Multivariate-adjusted 1.00 Referent 1.01 0.85, 1.20 1.01 0.85, 1.19 1.28 1.08, 1.51 0.001 1.18 1.11, 1.25
3-Hydroxyanthranilic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.91 0.78, 1.05 0.85 0.73, 0.98 0.98 0.86, 1.13 0.684 0.98 0.93, 1.03
Multivariate-adjusted 1.00 Referent 0.96 0.83, 1.12 0.88 0.76, 1.03 1.07 0.93, 1.24 0.539 1.00 0.95, 1.06
Xanthurenic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.83 0.72, 0.95 0.81 0.70, 0.93 0.86 0.74, 0.98 0.021 0.89 0.85, 0.94
Multivariate-adjusted 1.00 Referent 0.86 0.75, 0.99 0.83 0.72, 0.96 0.87 0.75, 1.01 0.041 0.89 0.85, 0.94
Abbreviations: CI, confidence interval; HR, hazard ratio.
a HR (and 95% CI) per standard-deviation increment of log-transformed exposure.
b The multivariate-adjusted model adjusted for sex, age group (46–49 years vs. 70–74 years), body mass index (weight (kg)/height (m)2;
continuous), smoking (never, former, or current smoker), and estimated glomerular filtration rate (continuous).
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Figure 2. Associations of 10 biomarkers (neopterin, kynurenine:tryptophan ratio (KTR), C-reactive protein (CRP), tryptophan, kynurenine, anthra-
nilic acid (AA), kynurenic acid (KA), 3-hydroxykynurenine (HK), 3-hydroxyanthranilic acid (HAA), and xanthurenic acid (XA)) with all-causemortality
in the Hordaland Health Study, 1998–2012. Models were constructed by using generalized additive model regression with adjustment for sex, age,
body mass index (weight (kg)/height (m)2), smoking, physical activity, and renal function (estimated glomerular filtration rate). The solid lines show
hazard ratios and the shaded areas 95%confidence intervals. Density plots indicate the distributions of the biomarkers, and dashed lines denote the
5th, 50th, and 95th percentiles. All exposure data were log-transformed before being entered into the models.
Table 3. Multivariate-Adjusteda Hazard Ratiosb for Cause-Specific Mortality According to Levels of Inflammatory
Markers and Kynurenine Pathway Metabolites (n = 7,010), Hordaland Health Study, 1998–2011
Biomarker
Cause of Death
Cancer
(n = 465)
CVD
(n = 385)
Other Diseases
(n = 410)
External Causes
(n = 50)c
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Neopterin, nmol/L 1.10 0.98, 1.24 1.32 1.19, 1.47 1.23 1.10, 1.36 1.16 0.90, 1.49
Kynurenine:tryptophan ratio,
nmol/µmol
1.20 1.07, 1.34 1.22 1.09, 1.37 1.19 1.07, 1.33 1.00 0.70, 1.42
C-reactive protein, mg/L 1.01 0.90, 1.13 1.38 1.21, 1.57 1.16 1.01, 1.33 0.92 0.69, 1.21
Tryptophan, µmol/L 0.90 0.82, 0.98 0.90 0.81, 0.99 0.85 0.77, 0.93 1.11 0.80, 1.52
Kynurenine, µmol/L 1.10 0.98, 1.24 1.14 1.00, 1.30 1.03 0.91, 1.17 1.15 0.76, 1.73
Anthranilic acid, nmol/L 1.07 0.96, 1.19 1.14 1.02, 1.28 1.05 0.93, 1.18 1.14 0.84, 1.55
Kynurenic acid, nmol/L 0.90 0.80, 1.01 1.08 0.96, 1.23 1.02 0.89, 1.17 0.95 0.66, 1.35
3-Hydroxykynurenine, nmol/L 1.02 0.92, 1.12 1.20 1.05, 1.32 1.24 1.10, 1.40 0.98 0.71, 1.35
3-Hydroxyanthranilic acid, nmol/L 1.06 0.96, 1.16 0.96 0.87, 1.06 1.00 0.90, 1.11 0.96 0.69, 1.33
Xanthurenic acid, nmol/L 0.90 0.82, 0.98 0.88 0.79, 0.98 0.97 0.87, 1.08 0.89 0.60, 1.33
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.
a Adjusted for sex, age group (46–49 years vs. 70–74 years), body mass index (weight (kg)/height (m)2;
continuous), smoking (never, former, or current smoker), and estimated glomerular filtration rate (continuous).
b HR (and 95% CI) per standard-deviation increment of log-transformed exposure, obtained by means of
competing-risk models.
c Deaths due to accidents, violence, poisoning, suicide, etc.
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the entire cohort, except for kynurenine, which had no signif-
icant association with risk of all-cause mortality (data not
shown). In addition, repeating the analyses after excluding
those who died during the ﬁrst 5 years of follow-up (n = 334)
yielded results similar to those reported in Table 2 (data not
shown).
Cause-speciﬁc mortality analyses (Table 3) showed that all
markers except KA and HAA were related to CVD death.
Neopterin, KTR, CRP, tryptophan, and HK were also related
to death from other diseases, whereas only KTR, tryptophan,
and XA were related to death from cancer. Thus, it appears
that plasma inﬂammatory markers and kynurenines were
more associated with CVD mortality than with cancer mor-
tality or mortality due to other diseases.
When participants with a history of cancer, CVD, or dia-
betes at baseline were excluded from the analysis, risk esti-
mates were essentially unchanged for cancer mortality and
mortality due to other diseases. For CVDmortality, however,
the associations remained signiﬁcant for neopterin and CRP,
whereas the associations were no longer signiﬁcant for all
other metabolites (data not shown).
DISCUSSION
Principal findings
In the present study, we identiﬁed plasma inﬂammatory
markers (neopterin, KTR, and CRP), kynurenine, AA, HK,
tryptophan (inversely), and XA (inversely) as independent
predictors of all-causemortality in a general populationduring
a median follow-up period of 14 years. These associations
persisted in analyses in which participants with baseline can-
cer, CVD, or diabetes mellitus were excluded or the ﬁrst 5
years of follow-up were excluded. KTR and tryptophan were
signiﬁcantly associated with death due to cancer, CVD, or
other diseases. CVD mortality correlated with the highest
number of biomarkers (all except KA and HAA).
Inflammatory markers, the kynurenine pathway, and
mortality
In this large-scale cohort of community-dwelling middle-
aged and older adults, we found that neopterin and KTRwere
associated with all-cause mortality, with risk estimates simi-
lar to those for patients with speciﬁc conditions (6–9). Such
associations have not been previously reported in the general
population. Our ﬁndings on CRP also resemble results previ-
ously reported (13, 14, 20). The 2 interferon-γ-mediated in-
ﬂammatory markers appeared to be better than the nonspeciﬁc
inﬂammatory marker CRP for the prediction of non-CVD
mortality, whereas CRP seemed slightly better for the predic-
tion of CVD mortality. However, no strong conclusion can be
made on the basis of the presented data. Other than for KTR,
associations of tryptophan and individual kynurenines with
mortality risk have not previously been reported.
Possible mechanisms
Systemic inﬂammation is involved in the pathophysiology
of a large number of chronic conditions, including CVD (33),
cancer (34, 35), and diabetes mellitus (16). Notably, all of the
10 predictors except HAAwere signiﬁcantly associated with
CVD mortality as compared with non-CVD mortality. This
indicates that inﬂammation may be more important for
CVD-related pathogenesis and death than for that related to
other conditions. This is in line with the current knowledge
of atherosclerosis, the major underlying cause of CVD, as a
chronic inﬂammatory process in which immune mechanisms
interact with metabolic risk factors to initiate, propagate, and
activate arterial lesions (6, 36, 37).
Positive associations of neopterin and KTR with mortality
risk indicate a role of interferon-γ activity and T-helper 1-
type cellular immune activation (12). Evidence suggests a
role of interferon-γ in CVD pathogenesis (6). We previously
reported that neopterin is associated with cancer risk (11),
and we observed a similar magnitude for the association with
cancer mortality in this study, although the ﬁnding was non-
signiﬁcant, probably because of fewer events.
Activation of the kynurenine pathway has been involved in
the pathophysiology of chronic disorders (5, 38). We ob-
served associations of both tryptophan (inverse) and kynure-
nine (positive) with all types of deaths due to diseases, albeit
weaker than the associations for KTR. Tryptophan depletion
via indoleamine 2,3-dioxygenase is part of the cytostatic and
antiproliferative activity mediated by interferon-γ in mono-
cyte-derivedmacrophages and dendritic cells (2, 12). In states
of persistent immune activation, however, a low tryptophan
concentration is likely to decrease the response of stimulated
T-cells and contribute to immunosuppression and immuno-
deﬁciency (5, 12).
XAwas inversely associated with mortality risk, especially
deaths due to cancer or CVD. The biological function of XA
remains obscure. However, XA has been shown to be a pow-
erful antioxidant due to its metal-chelating activity, and it
also serves as a peroxyl radical scavenger (39).
Although AA is generally accepted to be biologically inert
(39), we observed a weak positive association with CVD
mortality. HK, which has been reported to be positively re-
lated to several inﬂammatory markers (29, 40), had the stron-
gest association with CVDmortality and noncancer mortality
among all of the individual kynurenines in the present study.
HK has also been shown to be inversely related to plasma
pyridoxal 5′-phosphate (vitamin B6), levels of which are de-
creased in persons with CVD (41). In contrast, we observed
no association of HAA with mortality risk, although HAA
has been shown to have beneﬁcial effects on lipid metabo-
lism, inﬂammation, and atherosclerosis in recent experimen-
tal studies (42, 43). Controversial ﬁndings have been reported
on pro- and antioxidant properties of HK and HAA (38).
Similarly, the U-shaped association of KA with mortality in
our study may be due to its combined pro- and antioxidant
properties (39, 44, 45).
Strengths and limitations
To our knowledge, this is the ﬁrst study to have prospec-
tively assessed the risks of all-cause and cause-speciﬁc mor-
tality associated with interferon-γ-mediated inﬂammatory
markers and metabolites of the kynurenine pathway in a gen-
eral population sample. The main strengths of this study
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include the large sample size and the long and nearly com-
plete follow-up. In addition, all main biomarker analyses
were performed at the same laboratory. The study included
10 different markers, which facilitated an extensive explora-
tion of exposure-outcome associations. Most biomarkers are
stable in stored plasma samples, and all have fair-to-good
within-person reproducibility (46) that allows single-time-
point measurement of biomarker status and suggests moder-
ate regression dilution bias. Since all-cause mortality is a
nonspeciﬁc endpoint of disease risk and prognosis, we addi-
tionally included cause-speciﬁcmortality to aid the discussion
of mechanisms. However, our study had several limitations.
Information on CVD and diabetes at baseline may have been
subject tomisclassiﬁcation due to the reliance on self-reporting.
Another limitation was the adjustment for kidney function by
eGFR, an imperfect measure. Thus, we cannot rule out the pos-
sibility of residual confounding. In addition, the study cohort
was from a small geographical area representing 2 narrow age
groups, which may limit the generalizability of the ﬁndings.
Conclusions
Our study showed that interferon-γ-mediated inﬂamma-
tory markers (neopterin and KTR), tryptophan, and several
kynurenines, in addition to CRP, were associated with all-
cause and cause-speciﬁcmortality in a large community-based
population. Notably, interferon-γ-mediated inﬂammation
and activation of the kynurenine pathway seem to have a
stronger relationship with CVD mortality than with mortality
due to cancer or other causes, possibly highlighting the role
of systemic inﬂammation and immune system activation in
the development of CVD.
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Appendix Table 1. Hazard Ratios for All-Cause Mortality According to Quartile of Kynurenine Concentration (Additionally Adjusted for Neopterin
Level) Among 7,015 Participants in the Hordaland Health Study, 1998–2012
Kynurenine
Quartile of Kynurenine Concentration
P for Trend
Continuousa
1 2 3 4
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Kynurenine, µmol/L
Sex- and age-adjusted 1.00 Referent 0.86 0.72, 1.03 0.87 0.73, 1.02 1.10 0.94, 1.29 0.027 1.09 1.03, 1.16
Multivariate-adjustedb 1.00 Referent 0.88 0.73, 1.06 0.86 0.72, 1.02 0.98 0.82, 1.18 0.813 1.01 0.95, 1.08
Anthranilic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.90 0.75, 1.07 0.91 0.77, 1.07 1.05 0.90, 1.23 0.180 1.05 1.00, 1.11
Multivariate-adjusted 1.00 Referent 0.92 0.77, 1.10 0.98 0.82, 1.16 1.07 0.90, 1.27 0.197 1.05 0.99, 1.11
Kynurenic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.74 0.63, 0.87 0.72 0.62, 0.84 0.90 0.78, 1.03 0.460 1.00 0.95, 1.05
Multivariate-adjusted 1.00 Referent 0.79 0.67, 0.94 0.74 0.63, 0.87 0.83 0.71, 0.98 0.048 0.96 0.90, 1.02
3-Hydroxykynurenine, nmol/L
Sex- and age-adjusted 1.00 Referent 0.97 0.81, 1.15 0.98 0.83, 1.15 1.28 1.10, 1.49 <0.001 1.18 1.12, 1.24
Multivariate-adjusted 1.00 Referent 0.98 0.82, 1.16 0.95 0.80, 1.12 1.12 0.94, 1.32 0.157 1.10 1.04, 1.17
3-Hydroxyanthranilic acid,
nmol/L
Sex- and age-adjusted 1.00 Referent 0.91 0.78, 1.05 0.85 0.73, 0.98 0.98 0.86, 1.13 0.684 0.98 0.93, 1.03
Multivariate-adjusted 1.00 Referent 0.94 0.81, 1.10 0.85 0.73, 0.99 1.02 0.88, 1.18 0.918 0.99 0.94, 1.04
Xanthurenic acid, nmol/L
Sex- and age-adjusted 1.00 Referent 0.83 0.72, 0.95 0.81 0.70, 0.93 0.86 0.74, 0.98 0.021 0.89 0.85, 0.94
Multivariate-adjusted 1.00 Referent 0.90 0.78, 1.04 0.87 0.75, 1.00 0.90 0.77, 1.04 0.120 0.91 0.86, 0.96
Abbreviations: CI, confidence interval; HR, hazard ratio.
a HR (and 95% CI) per standard-deviation increment of log-transformed exposure.
b The multivariate-adjusted model adjusted for sex, age group (46–49 years vs. 70–74 years), body mass index (weight (kg)/height (m)2;
continuous), smoking (never, former, or current smoker), estimated glomerular filtration rate (continuous), and neopterin (log-transformed).
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